Butzkueven, H. Et Al. 2015. Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.. 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS) , (Seoul, South Korea), 418-419.

Butzkueven, H., Spelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., ... Wiendl, H.(2015). Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS. . 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS) (pp.418-419). Seoul, South Korea

Butzkueven, H. Et Al. "Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.," 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul, South Korea, 2015

Butzkueven, H. Et Al. "Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.." 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS) , Seoul, South Korea, pp.418-419, 2015

Butzkueven, H. Et Al. (2015) . "Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.." 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS) , Seoul, South Korea, pp.418-419.

@conferencepaper{conferencepaper, author={H. Butzkueven Et Al. }, title={Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.}, congress name={8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS)}, city={Seoul}, country={South Korea}, year={2015}, pages={418-419} }